Tango Therapeutics to present updated vopimetostat + RAS(ON) combination data at European Society For Medical Oncology (ESMO) Congress 2026. Key Takeaway: Tango Therapeutics will present updated data from a Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP deleted RAS mutant metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer at the ESMO Congress 2026. The presentation is scheduled for October 25, 2026, with abstracts available on October 19, 2026. The company will also host a webcast to discuss these findings. Market sentiment analysis. Positive factors. * Tango Therapeutics is presenting updated data at a significant oncology congress. * The study focuses on a promising combination therapy for difficult-to-treat cancers. * The company is committed to precision medicine and innovative cancer treatments. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 7 past catalysts Cash runway Minimal dilution risk Lead asset Phase 1 · PDAC BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) Congress 2026, which will be held October 23-27, 2026 in Madrid, Spain. Abstracts will be available on the ESMO website on Monday, October 19, 2026,12:05 am CEST. The data cutoff in the abstract is as of April 3, 2026. The poster presentation will include updated data. Abstract accepted for poster presentation. Title: A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic PDAC and NSCLC Abstract #: 3149P Presenter: Alexander I. Spira, MD, PhD, FACP (NEXT Oncology, Fairfax, United States of America) Date, Time: Sunday, October 25, 2026, 12:00 - 12:45 pm CEST PDAC Investor Webcast and Conference Call Information The Company will host a PDAC focused investor webcast to discuss these data at 7:30 am ET on Friday, October 23, 2026. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.tangotx.com. The webcast will be available for replay for at least 30 days on the Company website. Analysts who wish to join the teleconference and participate in Q&A should register here. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango Therapeutics leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Tango Therapeutics. Forward-looking statements are not purely historical and may be accompanied by words such as "may", "should", "expect", "intend", "will", "goal", "estimate", "anticipate", "believe", "predict", "designed," "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: statements regarding: (i) the potential of the Company's PRMT5 molecules, as both standalone treatments and in combination with RAS(ON)-inhibitors; (ii) the Company's beliefs regarding the timing of upcoming clinical milestones and data disclosures and (iii) expectations regarding the anticipated benefits of the Company's molecules and product candidates. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango Therapeutics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risks described in the Company's filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as other filings the Company makes with the SEC from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company specifically disclaims any duty to update these forward-looking statements. Investors: elizabeth hickin [email protected]. Media: 1AB amanda lazaro [email protected]. Frequently asked questions. What is the focus of Tango Therapeutics' presentation? The presentation focuses on updated data from a Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib. When will the ESMO Congress 2026 take place? The ESMO Congress 2026 will be held from October 23-27, 2026, in Madrid, Spain. Who will present the updated data? Dr. Alexander I. Spira from NEXT Oncology will present the updated data. How can investors access the webcast? Investors can access the webcast under the 'Events & Presentations' section on Tango's website.

Tango Therapeutics to present updated vopimetostat + RAS(ON) combination data at European Society For Medical Oncology (ESMO) Congress 2026. Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET. BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) Congress 2026, which will be held October 23-27, 2026 in Madrid, Spain. Abstracts will be available on the ESMO website on Monday, October 19, 2026,12:05 am CEST. The data cutoff in the abstract is as of April 3, 2026. The poster presentation will include updated data. Abstract accepted for poster presentation Title: A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic PDAC and NSCLC Abstract #: 3149P Presenter: Alexander I. Spira, MD, PhD, FACP (NEXT Oncology, Fairfax, United States of America) Date, Time: Sunday, October 25, 2026, 12:00 - 12:45 pm CEST PDAC Investor Webcast and Conference Call Information The Company will host a PDAC focused investor webcast to discuss these data at 7:30 am ET on Friday, October 23, 2026. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.tangotx.com. The webcast will be available for replay for at least 30 days on the Company website. Analysts who wish to join the teleconference and participate in Q&A should register here. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango Therapeutics leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Tango Therapeutics. Forward-looking statements are not purely historical and may be accompanied by words such as "may", "should", "expect", "intend", "will", "goal", "estimate", "anticipate", "believe", "predict", "designed," "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: statements regarding: (i) the potential of the Company's PRMT5 molecules, as both standalone treatments and in combination with RAS(ON)-inhibitors; (ii) the Company's beliefs regarding the timing of upcoming clinical milestones and data disclosures and (iii) expectations regarding the anticipated benefits of the Company's molecules and product candidates. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango Therapeutics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risks described in the Company's filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as other filings the Company makes with the SEC from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company specifically disclaims any duty to update these forward-looking statements. Company Profile Tango Therapeutics, Inc. Industry: Pharmaceuticals & Biotechnology Website: https://tangotx.com Recommended reading.